ADHD drug gets three more dosage strengths

Article

Shire's ADHD treatment lisdexamfetamine (Vyvanse) was approved by the FDA in three new dosage strengths. The current 30 mg-, 50 mg and 70 mg-dosage strengths will be joined by 20 mg-, 40 mg-, and 60 mg-dosage strengths. They will be available in the second quarter of this year.

Lisdexamfetamine is approved to treat ADHD in children between 6 and 12 years of age. Many who receive treatment have their dose levels titrated up or down. These additional dosage strengths could offer a more gradual process in titrating, 10 mg at a time.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Peter S. Jensen, MD
Rakesh Jain, MD, MPH
Rakesh Jain, MD, MPH
Alan Percy, MD
Alan Percy, MD
Perry Roy, MD
Perry Roy, MD | Image Credit: Carolina Attention Specialists
Related Content
© 2025 MJH Life Sciences

All rights reserved.